Home › Compound Library › MDMA (Ecstasy)

MDMA (Ecstasy)

Empathogenoral · inferred

3,4-Methylenedioxymethamphetamine. Potent serotonin, dopamine, and norepinephrine releaser. Exhibits nonlinear pharmacokinetics (auto-inhibits CYP2D6). N-demethylated to MDA (active, longer half-life ~16h). Detectable in urine for 2-4 days.

Projected serum levels — 100 mg, as needed (shown daily)

MDMA (Ecstasy)
MDMA (Ecstasy) modeled serum levels, 100 mg as needed (shown daily) over 15 days Population-based pharmacokinetic estimate. Steady state reached after approximately 1 days. 0 25 50 75 100 Day 0 Day 4 Day 8 Day 11 Day 15 Time on a regular schedule ≈ steady state · day 1

Maintenance schedule: 100 mg as needed (shown daily) (oral).

Modeled steady state after ~1 days: peak ≈ 89.5 mg, trough ≈ 16.0 mg body load. Population-based estimate over 15 days for a 100 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Empathogen
Route modeled
Oral
Model confidence
inferred
Half-life
8.6 h
Common dose
100 mg
Reference dose range
50–200 mg (single dose)
Suggested cadence
as needed (shown daily)
Validated against
100 mg oral — Cmax 0.20 mg/L at 2 h

Documented interactions

  • contraindicated
    6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) + MDMA (Ecstasy) CYP inhibition

    MDMA (Ecstasy) mechanism_based of CYP2D6 predicted to change 6-APB (Benzofury / 6-(2-aminopropyl)benzofuran) AUC by ~10.00x

  • contraindicated
    Atomoxetine (Strattera) + MDMA (Ecstasy) CYP inhibition

    MDMA (Ecstasy) mechanism_based of CYP2D6 predicted to change Atomoxetine (Strattera) AUC by ~5.14x

  • contraindicated
    DOM (2,5-Dimethoxy-4-methylamphetamine / STP) + MDMA (Ecstasy) CYP inhibition

    MDMA (Ecstasy) mechanism_based of CYP2D6 predicted to change DOM (2,5-Dimethoxy-4-methylamphetamine / STP) AUC by ~10.00x

  • contraindicated
    Ibogaine + MDMA (Ecstasy) CYP inhibition

    MDMA (Ecstasy) mechanism_based of CYP2D6 predicted to change Ibogaine AUC by ~10.00x

  • contraindicated
    Metoprolol (Lopressor / Toprol-XL) + MDMA (Ecstasy) CYP inhibition

    MDMA (Ecstasy) mechanism_based of CYP2D6 predicted to change Metoprolol (Lopressor / Toprol-XL) AUC by ~5.14x

  • danger
    1P-LSD (1-Propionyl-LSD) + MDMA (Ecstasy) Serotonin risk

    1P-LSD (1-Propionyl-LSD) and MDMA (Ecstasy) both have serotonergic activity. Risk of serotonin syndrome (hyperthermia, rigidity, autonomic instability, altered mental status).

Serum checks 247 modeled interaction pairings for mdma (ecstasy) across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Non-Linear Pharmacokinetics of MDMA (Ecstasy) in Humans de la Torre R et al. · British Journal of Clinical Pharmacology, 2000 DOI

    Demonstrated dose-disproportional increases in MDMA plasma concentrations suggesting CYP2D6 auto-inhibition, with formation of MDA metabolite via O-demethylenation.

  2. Human Pharmacology of MDMA: Pharmacokinetics, Metabolism, and Disposition de la Torre R et al. · Therapeutic Drug Monitoring, 2004 DOI

    Detailed characterization of MDMA metabolism including CYP2D6-mediated demethylenation, catechol-O-methyltransferase activity, and MDA as a minor but pharmacologically active metabolite.

2 published studies referenced in the app, each with a plain-language summary.